Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
| Autor: | Nan-Ying Chiu, Po See Chen, Chau-Shoun Lee, Chih-Sung Liang, Tung-Ping Su, Ya Mei Bai, Joseph Kuo, Ming-Hsien Hsieh, Yung-Chieh Yen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
recommendation
medicine.medical_specialty medicine.drug_class Schizophrenia (object-oriented programming) medicine.medical_treatment Breastfeeding Medicine (miscellaneous) Atypical antipsychotic behavioral disciplines and activities Article aripiprazole mental disorders otorhinolaryngologic diseases Medicine In patient long-acting injectable antipsychotic Antipsychotic atypical antipsychotic expert consensus business.industry Expert consensus schizophrenia Long acting Family medicine Aripiprazole business guidance medicine.drug |
| Zdroj: | Journal of Personalized Medicine, Vol 11, Iss 1198, p 1198 (2021) Journal of Personalized Medicine Volume 11 Issue 11 |
| ISSN: | 2075-4426 |
| Popis: | In the last decade, long-acting injectable antipsychotics has been widely used in schizophrenia. Aripiprazole long-acting once-monthly (AOM) is the only long-acting dopamine partial agonist antipsychotic approved for schizophrenia however, a literature search revealed no guidance on safely switching from oral and long-acting injectable antipsychotics to AOM. This study aimed to develop recommendations of AOM use based on existing data and expert consensus. A committee of 30 experts in psychopharmacology from major hospitals across Taiwan was invited. A modified Delphi method was conducted, consisting of two rounds of questionnaires, literature review, three rounds of face-to-face discussion meeting, and two rounds of anonymous voting. The consensus recommendations were developed based on existing data, clinical experiences, and consensus opinions, with 80% agreement among panel members required for final adoption. The panel developed nine consensus statements of switching to AOM for both acute and stable schizophrenia patients receiving oral or long-acting injectable atypical antipsychotics. Recommendations regarding dose adjustment of oral medication and pregnancy/breastfeeding were also included. The nine consensus recommendations provide a guidance on safely switching to AOM. Substantial gaps in knowledge, and more research is necessary. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|